Posts

Showing posts from 2021

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES⚕️ (1)Bharat Biotech’s ROTAVAC 5D receives WHO pre-qualification. It's the only rotavirus vaccine in the world to be delivered in a 0.5 ml dose volume. Bharat Biotech has announced that the World Health Organization (WHO) has awarded pre-qualification to its rotavirus vaccine, ROTAVAC 5D. The new variant of ROTAVAC, ROTAVAC 5D, is a rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children, the company said in a statement. (2)Glenmark inks agreement with SaNOtize to commercialise nasal spray for COVID-19 treatment in India and other Asian markets Nitric oxide (NO) has anti-microbial properties with a direct proven effect on SARS-CoV-2. Glenmark Pharmaceuticals and SaNOtize Research & Dev

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1.Zydus vaccine for children above 12 years could be available by August. National technical advisory board group of Immunisation ( NTAGI ) chairman Dr Arora also added that the trials are likely to be Completed by the end of next month. 2.India achieve milestone of conducting 40 crores Covid sample testing. India has tested 40,18,11,892 samples across the nation till 25 June 2021 The Indian council of Medical Research said. 251 doctors Challenge Govt. FIR Diktat. -Ahmedabad: A group of 251 graduate students and super-specialists practicing in Gujarat approach the Gujarat High Court to challenge the decision of the state government to join Covid-19’s obligations and call for obligations. I submitted a FIR as not responding. 4. Serum institute of India produce more than 10 crore Doses of covishield in June. The Drugs Controller General of India (DCGI) on Sunday said that the Serum Institute of India has produced 10 crore

ANTIBIOTICS RESISTANCE

Image
ANTIBIOTICS RESISTANCE Some of these mutations make microbes less susceptible to the effects of antimicrobials, a phenomenon known as antimicrobial resistance. (WHO) defines antimicrobial resistance (AMR) as “resistance of a microorganism to an antimicrobial drug that was originally effective for treatment of infections caused by it.” Resistance occurs when an antimicrobial has lost its ability to effectively control or eliminate a microbial infection against which it was once effective. The microbes are then considered “resistant” and are able to continue to replicate even when the antimicrobial is present. While many people are aware that bacteria can develop antibiotic resistance, resistance also occurs in viruses, parasites, and fungi. Approximately 700,000 deaths worldwide can be attributed to AMR each year, a figure that is poised to jump to 10 million by 2050 if actions are not taken to combat its spread. HOW DOES AMR OCCUR? Some microbes are pre-progra

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1. Covid 19 Vaccine effective for at least 1 year :- Karnataka Virologist. Karnataka based Virologist Dr V Ravi said that available evidence suggests that vaccinated person would get protection for two to three years If more troubling Variants don't emerge. 2.Indian Immunologicals to begin Drug substance production for Covaxin from June. Indian Immunological Limited has announced it's plan to start the production of drug substance for Covaxin From June and Despatch the first Batch to Bharat Biotech by July. 3. Zydus Cadilla plans test for its Covid Vaccine in 5 to 12 years age group. Zydus Cadilla is planning to start Clinical trials of its Covid Vaccine, ZycoV-D, in children of 5 to 12 years age group. 4. Modern laboratories to mfg. Amphotericin B. Amphotericin B is Used for treatment of Black Fungus, White Fungus and Yellow Fungus. 5.IIT Hyderabad researchers develop oral an solution to treat black

FDA authorizes additional monoclonal antibody for treatment of COVID-19.

Image
FDA authorizes additional monoclonal antibody for treatment of COVID-19. The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions. The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. This treatment has not shown benefit in patients hospitalized due to COVID-19 and monoclonal anti

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1.AstraZeneca gets European union approval for early lung cancer drug  The approval was given based on good results from late stage trials which showed Tagrisso drug minimize risk of tumour growing back in cancer patient or death by 80%. 2.Bajaj Health care launched drug for Mucormycosis. Company received nod from FDA India to Mfg. and market Posaconazole API for treating Black Fungus. 3.AstraZeneca and Abott cancel distribution aggrement for diabetes drug. AstraZeneca India will continue to market Forxiga, Xigduo and Qtern. 4.Sun Pharma acquire rights to Trademark of 3 diabetes drug brand in India from AstraZeneca. Sun Pharma acquire rights of trademark of Oxra, Oxramet and Oxraduo in India from AstraZeneca Pharma India Ltd. Parent Company. 5.Glenegels global health city Hospital collaborate with Cipla for Covid drug. Both collaborated to launch Roches's Antibody drug Cocktail for early stage Covid treat

PHARMA BULLETIN⚕️

Image
PHARMA UPDATES ⚕️ 1.BDR Pharma launches drug to treat advances tage Ovarian and Prostate Cancer. BDR Pharma has launched Rucaparib under brand name BDPARIB. It first affordable drug treat Ovarian and Prostate Cancer. 2.Seeking Pills to cure Covid Pharma Companies eye alternative to vaccine. Many drug makers are working on so called oral antivirals which would copy what drug Tamiflu does for Influenza. 3.Lupin gets $50 Million from Boehringer for anticancer drug. Lupin has received payment of around Rs.363.5 Crore from Boehringer Ingelheim for achievement of key milestones by its cancer drug potential drug therapy for cancer patients. 4.Agrrement signed b/w Bharat Biotech Gujarat Covid Vaccine Consortium. Memorandum of understanding (MoU) has signed b/w Bharat Biotech and Gujarat Covid Vaccine Consortium for contract Mfg.drug substance for Covaxin. 5.Zydus Cadilla has sought drugs Controller General of India (DCGI)  Approval to

PHARMA BULLETIN ⚕️

Image
1.Indian Medical Association writes to PM Narendra Modi on Ramdev statement. The Indian Medical Association appeal to PM Narendra Modi to take strict action against Ramdev over his statement questioning the efficacy of Allopathy drugs and Doctors. 2.Zydus Cadilla and TLC Ink Pact to market Liposomal Amphotericin B. Zydus Cadilla and Taiwan based Pharma firm TLC have signed an agreement to market Liposomal Amphotericin B, a drug for treatment of Mucormycosis. 3.VAV Life Sciences to increase lipid production for black fungus drug. VAV Life Sciences is ramping up production of crucial lipid ingredients used in making Liposomal Amphotericin B. 4.Our Covid Vaccine highly effective Pfizer to Govt. Pfizer has told Indian Govt.that vaccine has shown high effectiveness against SARS-COV-2 varriant prevalent in India. While suitable for everyone age 12 yrs or above and stored for month 2-8 degree Celsius temperature. 5.20 Crore dose give

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1. Recovery rate of 14 states now 90 % or above. 14 states and union Territories have reached a Covid recovery rate of 90 % and above. The highest recovery rate is in Delhi at 97% followed by Uttar Pradesh, Bihar and Haryana at 94% each. 2.IQVIA Biotech announces expansion in Asia Pacific and Japan. IQVIA Biotech announced the expansion in Japan and Asia Pacific (JAPAC) a tailored approach to delivering integrated Clinical and commercial solutions for biotech and emerging biopharma companies. 3. Bal Pharma launches Favipiravir formulation. An Anti viral drug is named as BALflu. The drug made is for the treatment of mild to moderate Covid Infection in patients.  4.The third Booster dose, after it gets Cleared by the authorities, would be administered to the beneficiaries Six months after they get the  second dose of covaxin. 5.I2Cure Bioshield was 97% effective against Sars-Cov 2. The Center for cellular and M